Rigel Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Stock-based Compensation (Tables)

Stock-based Compensation (Tables)

9 Months Ended

Sep. 30, 2015

Schedule of stock-based compensation expense related to all of the entity's share-based awards

Total stock-based compensation expense related to all of our share-based payments that we recognized for the three and nine months ended September 30, 2015 and 2014 were as follows (in thousands):


	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2015		2014		2015		2014
Research and development	$	966	$	1,151	$	3,182	$	3,654
General and administrative		849		929		2,596		2,922
Total stock-based compensation expense	$	1,815	$	2,080	$	5,778	$	6,576

Summary of weighted-average assumptions relating to options granted pursuant to equity incentive plans


	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2015		2014		2015		2014
Risk-free interest rate	1.9	%	2.2	%	1.8	%	2.2	%
Expected term (in years)	6.0		6.0		6.5		6.6
Dividend yield	0.0	%	0.0	%	0.0	%	0.0	%
Expected volatility	59.6	%	67.1	%	65.0	%	74.9	%

Summary of weighted-average assumptions used to calculate fair value of purchase rights granted under Employee Stock Purchase Plan


	Nine Months Ended
	September 30,
	2015		2014
Risk-free interest rate	0.6	%	0.3	%
Expected term (in years)	1.5		1.7
Dividend yield	0.0	%	0.0	%
Expected volatility	61.2	%	66.0	%